Phase 1 Start
DARE: Phase 1 Start: An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone
September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- Dare Bioscience, Inc. (DARE)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone
- Company
- Dare Bioscience, Inc. (DARE)